Parameters that influence the outcome of nausea and emesis in cisplatin based chemotherapy

Citation
N. Tsavaris et al., Parameters that influence the outcome of nausea and emesis in cisplatin based chemotherapy, ANTICANC R, 20(6C), 2000, pp. 4777-4783
Citations number
30
Categorie Soggetti
Onconogenesis & Cancer Research
Journal title
ANTICANCER RESEARCH
ISSN journal
02507005 → ACNP
Volume
20
Issue
6C
Year of publication
2000
Pages
4777 - 4783
Database
ISI
SICI code
0250-7005(200011/12)20:6C<4777:PTITOO>2.0.ZU;2-9
Abstract
Some factors have demonstrated an influence on emesis and antiemetic respon se. In order to study these factors, 306 patients (pts) entered this study receiving cisplatin based combination chemotherapy (CT) (100 mg/m(3), with onciansetron (8 mg, 3 times daily for 4 days) as the only antiemetic treatm ent. Known factors that influence the result of antiemetic therapy such as age, sex, performance status (Karnofsky), site of primary tumor, weight los s, anxiety, depression, psychological problems related to CT (psychological PRC) etc, were included in the evaluation. We evaluated the number of vomi ts, retches and nausea. The existence of psychological PRC was found to be a prominent factor far the development of nausea and emesis, being at the s ame time strongly associated with scaling variables (Gralla, retching and n ausea grading) used to measure the severity of nausea and emesis (p=0.001). Stress was also a significant predictor; patients with stress had an almos t two times higher probability to develop nausea or retching compared to pa tients without stress indications (p=0.001), while the occurrence of retchi ng was marginal. Younger patients (less than 40 years old) were found to be almost three times more susceptible to retching compared to older patients (more than 40 years old) (P 0.006). With all possible evaluations, we conc luded that significant factors are psychological PRC, stress and age. In co nclusion, three factors, age, stress and psychological PRC, should be taken seriously into consideration in the design of future trials evaluating ant iemetic treatment, as well as in the every-day clinical practice, in order to provide patients with a better quality of life during emetogenic CT.